CBUS
$2.48-0.18 (-6.77%)
Cibus, Inc., an agricultural biotechnology company, develops and licenses gene edited plant traits using gene editing technologies to enhance farming productivity or produce renewable low carbon plant products.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Cibus, Inc., an agricultural biotechnology company, develops and licenses gene edited plant traits using gene editing technologies to enhance farming productivity or produce renewable low carbon plant products. It focuses on trait productivity in the...
Recent News
Cibus, Inc. Q4 2025 Earnings Call Summary
Moby summary of Cibus, Inc.'s Q4 2025 earnings call
Cibus Q4 Earnings Call Highlights
Cibus (NASDAQ:CBUS) used its fourth quarter 2025 results call to highlight a year the company described as a commercial and regulatory inflection point for gene editing in agriculture, citing expanding customer traction in rice, early revenue in sustainable ingredients, and what management called “w
Cibus Inc (CBUS) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
Cibus Inc (CBUS) showcases significant technological progress and strategic partnerships, despite reporting increased net losses and financial constraints.
Cibus (CBUS) Q4 2025 Earnings Call Transcript
By any measure, 2025 was a landmark year for Cibus, Inc., not because of any single headline, but because of a convergence of key themes that are shaping the trajectory of the gene editing industry. Gene editing is no longer an experiment. What makes this current moment particularly exciting is the intersection of our technology readiness and a change in how we believe seed companies are thinking about gene editing.
Cibus (CBUS) Reports Q4 Loss, Lags Revenue Estimates
Cibus (CBUS) delivered earnings and revenue surprises of +2.33% and -27.85%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?